LSZ is chemically related to LSD active at similar dosages, with one of its isomers more potent in rats than d-LSD. LSZ sold on white blotter became commercially available in mid 2013. LSZ is one of a group of ergoloids developed by David Nichols' lab at Purdue in the early 2000s, but there are unconfirmed reports that LSZ was previously available on blotter prior to Nichols' first publication. LSZ has three stereoisomers, one (S,S) is substantially more potent than the other three.